SequelSEC

ROCKET PHARMACEUTICALS, INC. RCKT

Pharmaceutical Preparations · CIK 0001281895 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$191.64M
Fiscal year ended 2026-06-30
Free cash flow
-$170.39M
Fiscal year ended 2026-06-30

ROCKET PHARMACEUTICALS, INC. (RCKT) reported revenue of $0 and net income of -$17.25M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ROCKET PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ROCKET PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$191.64M
Net income-$17.25M
Research & development$124.37M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$67.52M
Selling & marketingUnavailable

Balance

ROCKET PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$224.51M
Total assets$423.10M
Current assets$289.55M
Total liabilities$54.27M
Current liabilities$31.32M
Total equity incl. NCI$368.83M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$39.15M
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

ROCKET PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$170.27M
Capital expenditures$127.00K
Investing cash flow$361.85M
Financing cash flow$82.00K
Net change in cashUnavailable
Stock-based compensation$31.78M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$7.60M

Derived

ROCKET PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$170.39M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio9.24x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RCKT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.